Mountain View, CA-based Versartis, the developer of protein drugs for endocrine disorders, said today it has raised $21 million in its Series B financing. The deal was led by New Leaf Venture Partners and Advent Venture Partners’ Advent Life Sciences fund, and included existing investors Index Ventures and Amunix. The company plans to use the money to run clinical trials of a once-monthly injectible form of human growth hormone for adults and children with deficiencies.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
